Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)

Drug (Brand / Generic)

Spinraza / nusinersen

Company / Licensee

Ionis Pharmaceuticals / Biogen

Therapy Class

Anti-sense therapy

Product Description

Anti-sense oligonucleotide

Current Indication

Spinal muscular atrophy

Market Sector

Central nervous system

Development Status

Approved in the US, marketing approval under review in Europe, Japan, Canada, and Australia
Expand

Go Top